• PUK29 DEVELOPING A MAPPING ALGORITHM TO PREDICT EQ-5D VALUES FROM SYMPTOM SCALES IN PATIENTS WITH BLADDER PAIN SYNDROME

    Nov 1, 2019, 00:00

  • PRO74 TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST THREE YEARS

    Nov 1, 2019, 00:00

  • PDG99 PATIENT'S PREFERENCES REGARDING DIRECT ORAL ANTICOAGULANTS SELECTION: RELEVANT CRITERIA FOR ROUTINE CLINICAL DECISION MAKING?

    Nov 1, 2019, 00:00

  • PCN48 FEASIBILITY OF EXTRACTING SURVIVAL DATA FROM PUBLISHED LITERATURE USING THE GUYOT ALGORITHM

    Nov 1, 2019, 00:00

  • RARE Process of Care

    Nov 1, 2019, 00:00

  • PCV125 DIFFERENCES ACROSS HEART FAILURE PATIENTS' CHARACTERISTICS, DISEASE EXPERIENCE AND QUALITY OF LIFE IN SHANGHAI COMPARED WITH REST OF CHINA

    Nov 1, 2019, 00:00

  • PCN205 COMPARISON OF METHODS TO ACCOUNT FOR CURED PATIENTS IN A COST-EFFECTIVENESS ANALYSIS: A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PMU46 POSITIVE IMPACT OF INNOVATIVE STATUS IN PR PROCESS TIMING IN ITALY

    Nov 1, 2019, 00:00

  • PNS236 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE IN EARLY ACCESS PROGRAM VS THE OTHERS IN FRANCE

    Nov 1, 2019, 00:00

  • PMH69 RISING DEPENDENCE ON ANTI-DEPRESSANTS AMONG ADULTS IN US: A STUDY BASED ON NHANES FROM 2005 TO 2016

    Nov 1, 2019, 00:00

  • PDG63 ASSESMENT OF ACCESS TO INNOVATIVE MEDICINES IN UKRAINE

    Nov 1, 2019, 00:00

  • PRO55 COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS COMPARED WITH NINTEDANIB FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PDB56 ECONOMIC IMPACT OF TYPE 2 DIABETES AND DIABETES-ASSOCIATED COMPLICATIONS: A LARGE CLAIMS-BASED STUDY

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • Infectious Diseases - Medical Technologies

    Nov 1, 2019, 00:00

  • RE3 A PROPOSED, SCALABLE APPROACH TO IMPLEMENTING INNOVATIVE PAYMENT AGREEMENTS

    Nov 1, 2019, 00:00

  • PIN80 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF CARBAPENEM-RESISTANT PATHOGENS ASSOCIATED WITH HEALTHCARE-ASSOSIATED INFECTIONS: A BUDGET IMPACT ANALYSIS IN ARGENTINA

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Organizational Practices

    Nov 1, 2019, 00:00

  • PNS324 A NOVEL APPROACH OF USING GRAPHICAL REPRESENTATION OF EQ-5D-3L DIMENSIONS, LEVELS, AND HEALTH STATES FOR ILLITERATE RESPONDENTS IN VALUATION STUDIES - AN EXAMPLE FROM MOROCCO

    Nov 1, 2019, 00:00

  • PNS262 EARLY DIALOGUE WITH NICE AND EUNETHTA: A UK PERSPECTIVE IN A POLITICALLY UNCERTAIN ERA

    Nov 1, 2019, 00:00

  • PCN358 COMPARING AND VALIDATING THE OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TREATMENTS APPLIED IN HTA'S BY NOMA AND TLV

    Nov 1, 2019, 00:00

  • PCN177 ORGANIZATIONAL AND ECONOMIC IMPACT OF NEXT GENERATION SEQUENCING AND HOTSPOT APPROACH

    Nov 1, 2019, 00:00

  • PCN287 THE ROLE OF EFFICACY AND EFFECTIVENESS ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS IN DETERMINING TENDERING RANKS FOR ONCOLOGY DRUGS IN DENMARK NORWAY

    Nov 1, 2019, 00:00

  • PDB44 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS LASER PHOTOCOAGULATION AND RANIBIZUMAB IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN CHINA

    Nov 1, 2019, 00:00

  • PNS61 DOES A STANDARD WILLINGNESS-TO-PAY THRESHOLD EXIST IN GREECE?

    Nov 1, 2019, 00:00

  • PCN101 COST-EFFECTIVENESS ANALYSIS OF TORIPALIMAB VERSUS PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA IN CHINA

    Nov 1, 2019, 00:00

  • Cancer - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PND11 IMPACT OF A COMMUNITY PHARMACY-BASED INFORMATION PROTOCOL ON MULTIPLE SCLEROSIS PATIENTS' ADHERENCE TO THEIR ORAL TREATMENT WITH DIMETHYL FUMARATE: TECPHIE, A RANDOMIZED STUDY VS USUAL PRACTICE (INTERIM RESULTS)

    Nov 1, 2019, 00:00

  • PMU148 CUTANEOUS LYMPHOMAS IN GERMANY: LANDSCAPING ANALYSIS OF GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA

    Nov 1, 2019, 00:00

  • PDB102 TARGETED LITERATURE REVIEW INTO METHODS OF DETERMINING PATIENTS' PREFERENCE FOR TREATMENT TYPE IN DIABETES

    Nov 1, 2019, 00:00

  • PCN521 THE FINANCIAL IMPACT OF AFATINIB REIMBURSEMENT FOR EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER: THE REAL-WORLD EVIDENCE IN TAIWAN

    Nov 1, 2019, 00:00

  • PND75 VALIDATION OF AN ALGORITHM IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS USING THE FRENCH NATIONWIDE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PNS21 REAL WORLD EVIDENCE (RWE) IN PARTITION SURVIVAL MODELLING: IS IT THE REAL DEAL?

    Nov 1, 2019, 00:00

  • PNS365 THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING: A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMU85 LESSONS FOR BREAKING NEW GROUND WITH FIRST-IN-CLASS THERAPIES

    Nov 1, 2019, 00:00

  • PDG109 REPLACING BRANDED ANTINEOPLASTIC DRUGS WITH GENERICS OR BIOSIMILARS: FORCAST OF BUDGET SAVINGS FOR THE PERSPECTIVE PERIOD

    Nov 1, 2019, 00:00

  • PNS173 MEASURING DELAYS IN THE AVAILABILITY OF NEW MEDICINES WITHIN EUROPE USING A TIME-TO-PRICE INDICATOR

    Nov 1, 2019, 00:00

  • The Joint Committee on Vaccination and Immunisation’s Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision?

    Nov 1, 2019, 00:00

  • PCN200 REAL-WORLD HEALTHCARE RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM MALIGNANT MELANOMA, A FINNISH REGISTRY STUDY

    Nov 1, 2019, 00:00

  • PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS

    Nov 1, 2019, 00:00

  • PMD14 COST-EFFECTIVENESS ANALYSIS OF THE USE OF MICROINVASIVE SURGERY WITH ISTENT® IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS IN THE MEXICAN PUBLIC HEALTH SYSTEM.

    Nov 1, 2019, 00:00

  • PNS218 SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: ESTABLISHING A EUROPEAN PICO

    Nov 1, 2019, 00:00

  • PDB61 THE CLINICAL AND ECONOMIC IMPACT OF ADDING AN ADHERENCE MODULE TO THE IQVIA CORE DIABETES MODEL

    Nov 1, 2019, 00:00

  • PNS204 THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS

    Nov 1, 2019, 00:00

  • PNS163 SHIFTING PARADIGM OF INTERNATIONAL REFERENCE PRICING. IS IT BENEFICIAL TO PAYERS, MANUFACTURERS OR PATIENTS?

    Nov 1, 2019, 00:00

  • CP3 DEVELOPING PROCESSES AND METHODS FOR A EUROPEAN COLLABORATION ON HTA: ACHIEVEMENTS, CHALLENGES AND LESSONS LEARNT

    Nov 1, 2019, 00:00

  • PNS358 DEVELOPMENT AND OPTIMIZATION OF NATIONWIDE INTEROPERABLE CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) IN KOREA

    Nov 1, 2019, 00:00

  • PCN394 DETERMINANTS OF MANAGED ENTRY AGREEMENTS IN THE CONTEXT OF HTA; EMPIRICAL EVIDENCE FROM ONCOLOGY MEDICINES IN FOUR COUNTRIES.

    Nov 1, 2019, 00:00

  • PUK18 THE ECONOMIC COST ASSOCIATED WITH NOCTURIA IN A WORKING-AGE POPULATION

    Nov 1, 2019, 00:00

  • PCN51 OUTCOMES MANAGEMENT IN A REAL WORLD EVIDENCE CONTEXT. THE CASE OF ABIRATERONE AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PSU27 ANALYSIS OF THE UTILIZATION OF ONE-DAY SURGERY AMONG CASES RELATED TO THE DISEASES OF THE MUSCULOSKELETAL SYSTEM OR CONNECTIVE TISSUE

    Nov 1, 2019, 00:00

  • PIN35 GLOBAL ANNUAL COSTS OF PEOPLE LIVING WITH HIV IN FRANCE IN 2013 FROM A NATIONAL INSURANCE CLAIMS DATABASE (SNIIRAM)

    Nov 1, 2019, 00:00

  • RARE Regulatory

    Nov 1, 2019, 00:00

  • PRS72 DRUG TREATMENT PATTERNS FOR PULMONARY ARTERIAL HYPERTENSION PATIENTS IN ENGLAND: A RETROSPECTIVE ANALYSIS USING HOSPITAL TREATMENT INSIGHTS DATABASE

    Nov 1, 2019, 00:00

  • PRO161 EPIDEMIOLOGY, HEALTHCARE RESOURCE CONSUMPTION AND RELATED COSTS FOR HYPOPHOSPHATEMIC VITAMIN D RESISTANT RICKETS PATIENTS IN AN ITALIAN REGION

    Nov 1, 2019, 00:00

  • PMU22 BROADER ECONOMIC BURDEN OF SMOKING ATTRIBUTABLE DISEASES IN GREECE

    Nov 1, 2019, 00:00

  • PGI32 EVALUATION OF THE COST-UTILITY OF THE YORK FAECAL CALPROTECTIN CARE PATHWAY

    Nov 1, 2019, 00:00

  • PCN268 ESTIMATING THE BURDEN OF MALIGNANT HAEMATOPOIETIC CANCERS IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS

    Nov 1, 2019, 00:00

  • PIT5 EXPERIENCE OF 2 INSTITUTIONS WITH THE GERIATRIC FRACTURE PROGRAM IN COLOMBIA: LENGTH OF STAY, MORTALITY AND ESTIMATION OF COSTS

    Nov 1, 2019, 00:00

  • PCN127 NUMBER NEEDED TO TREAT (NNT) AND COST OF PREVENTING AN EVENT (COPE) COMPARISON BETWEEN THE TRIPLETS DRD AND KRD FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA IN THE BRAZILIAN PRIVATE SYSTEM

    Nov 1, 2019, 00:00

  • PCN516 EXPLORING THE CURRENT STATUS OF NEUROENDOCRINE TUMOURS: A POPULATION-BASED ANALYSIS OF EPIDEMIOLOGY, MANAGEMENT AND USE OF RESOURCES

    Nov 1, 2019, 00:00

  • PBI75 REVIEW OF ECONOMIC EVALUATIONS FOR GENE THERAPIES:ARE WE READY FOR THE FUTURE?

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PNS50 ECONOMIC IMPACT OF THE DEVELOPMENT OF OUTPATIENT SURGERY IN FRANCE

    Nov 1, 2019, 00:00

  • PND79 HOW DIFFERENT ARE MIGRAINE PATIENTS TREATED BY GENERAL PRACTITIONERS VERSUS THOSE TREATED BY NEUROLOGISTS?

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PSY34 TWO SIDES OF THE SAME COIN? A DUAL MULTIPLE CRITERIA DECISION ANALYSIS OF NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS FROM PHYSICIANS' AND PATIENTS' PERSPECTIVES IN GREECE

    Nov 1, 2019, 00:00

  • PRO35 ANALYZING THE LEVEL OF EVIDENCE REQUIRED FOR ONCOLOGY VERSUS NON-ONCOLOGY ORPHAN DRUGS AS IT RELATES TO PRICE

    Nov 1, 2019, 00:00

  • PCN337 HTA DECISIONS IN FRANCE AND GERMANY: LESSONS FROM MELANOMA

    Nov 1, 2019, 00:00

  • PMU6 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF 5% LIDOCAINE-MEDICATED PLASTER VS. PREGABALIN

    Nov 1, 2019, 00:00

  • PMU25 USING MULTIPLE CRITERIA DECISION ANALYSIS (MCDA) TO CREATE A PRIORITY LIST OF CHRONIC NON-COMMUNICABLE DISEASES (NCDS) TO GUIDE HEALTH RESEARCH SPENDING

    Nov 1, 2019, 00:00

  • PNS177 BARRIERS TO PUBLIC PRIVATE PARTNERSHIPS IMPLEMENTATION IN HEALTHCARE SECTOR IN KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PMU61 IDENTIFYING DISEASE AREAS WHERE DISRUPTIVE INNOVATION IS LIKELY TO HAVE A SIGNIFICANT IMPACT ON HEALTHCARE SYSTEMS AND BUDGETS. THE IMPORTANCE OF TRACKING PAYER BEHAVIOURS

    Nov 1, 2019, 00:00

  • PCN219 WHAT IS WORTH KNOWING AT EARLY DEVELOPMENT? VALUE OF INFORMATION ANALYSIS USING AN INDICATION-AGNOSTIC WEB-BASED PLATFORM: A CASE STUDY

    Nov 1, 2019, 00:00

  • PCV111 REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) IN CARDIOLOGY AND DIABETOLOGY

    Nov 1, 2019, 00:00

  • PCN353 RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON NON-SMALL CELL LUNG CANCER: RESULTS, RATIONALE, AND TRENDS

    Nov 1, 2019, 00:00

  • PBI46 IMPLEMENTATION OF ADALIMUMAB BIOSIMILARS IN DENMARK

    Nov 1, 2019, 00:00

  • PCN469 DISEASE SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS FOR HEMATOLOGIC MALIGNANCIES (HM)

    Nov 1, 2019, 00:00

  • PRO47 COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS IN COMPARISON WITH BEST SUPPORTIVE CARE IN IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PNS137 ORPHAN DRUGS: WHAT FACTORS IMPACT THE PRICE IN FRANCE?

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PDG75 TRENDS IN THE USE OF PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS ARRANGEMENTS IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PND58 AN ECONOMIC EVALUATION ATTACHED TO A SINGLE-CENTRE, PARALLEL GROUP, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF AN THREE DAY INTENSIVE SOCIAL COGNITIVE TREATMENT (CAN DO TREATMENT) IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSI ...

    Nov 1, 2019, 00:00

  • PND106 LIVING WITH MIGRAINE: SUPPORT NEEDED AND HEALTHCARE EXPENDITURE ON BRAZILIAN PATIENTS FROM THE MY MIGRAINE VOICE SURVEY

    Nov 1, 2019, 00:00

  • PNS309 UTILIZING MACHINE LEARNING AND ECG DATA FOR CONTINUOUS USER AUTHENTICATION OF PATIENTS DURING A CLINICAL TRIAL

    Nov 1, 2019, 00:00

  • PDB26 THE BURDEN OF SEVERE HYPOPARATHYROIDISM IN GERMANY - A CLAIMS DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • PRS56 MACHINE LEARNING PREDICTION OF ASTHMA NON-SCHEDULED VISITS IN THE BRAZILIAN PRIVATE HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PNS364 PATIENT INVOLVEMENT IN EUNETHTA PHARMACEUTICAL JOINT CLINICAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • PNS380 BREAST CANCER PATIENT PERSPECTIVES ON IMPORTANT SYMPTOM INFORMATION

    Nov 1, 2019, 00:00

  • PCV81 CURRENT TRENDS IN LIPID LOWERING THERAPY USE IN GERMANY

    Nov 1, 2019, 00:00

  • PNS295 BEST WORST SCALING: FOR GOOD OR FOR BAD BUT NOT FOR BOTH

    Nov 1, 2019, 00:00

  • PDG31 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS LASER PHOTOCOAGULATION OR OBSERVATION FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION: FROM CHINESE SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PND7 EFFICACY OF VIRTUAL REALITY GLASSES AMONG PATIENTS WITH STROKE

    Nov 1, 2019, 00:00

  • PMU91 CURRENT TREND OF UTILITY VALUES IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISAL GUIDANCE

    Nov 1, 2019, 00:00

  • PCN472 PATIENT REPORTED HEALTH STATE UTILITIES IN CUTANEOUS T-CELL LYMPHOMA (CTCL) - AN ANALYSIS OF EQ-5D AND SKINDEX-29 DATA COLLECTED FROM THE ALCANZA TRIAL

    Nov 1, 2019, 00:00

  • PSY25 THE RELATIONSHIP BETWEEN PEANUT ALLERGY PREVALENCE AND THE DIFFERENT DIAGNOSTIC METHODS USED, ACROSS 5 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • Infectious Disease Studies

    Nov 1, 2019, 00:00

  • PND118 PATIENTS WITH CHRONIC PAIN DISORDERS: PREFERENCE OF EPRO SCREEN DISPLAY AND FEATURES

    Nov 1, 2019, 00:00

  • Drugs Generics - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PRO78 THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PBI8 UNKNOWN

    Nov 1, 2019, 00:00

  • PSY15 COMPARISONS OF COSTS RELATED TO THE INITIATION OF TAPENTADOL OR OXYCODONE TREATMENT IN SPANISH PATIENTS SUFFERING FROM SEVERE NON-MALIGNANT PAIN

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV37 BUDGET IMPACT ANALYSIS OF ANTIPLATELET THERAPY WITH CANGRELOR IN PATIENTS WITH ACUTE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SPAIN

    Nov 1, 2019, 00:00

  • PCN184 ECONOMIC EVALUATION OF CHECKPOINT INHIBITORS FOR THE TREATMENT OF ADVANCED MELANOMA IN THE IRISH HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PIN66 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME-AVIBACTAM VERSUS COLISTIN-MEROPENEM IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE IN COLOMBIA

    Nov 1, 2019, 00:00

  • PDB121 THE FINANCIAL IMPACT OF FEBUXOSTAT REIMBURSEMENT TO THE TAIWAN NATIONAL HEALTH INSURANCE

    Nov 1, 2019, 00:00

  • PSS22 FACTORS INFLUENCING AGREEMENT BETWEEN PATIENT AND CLINICIAN ASSESSMENTS OF SEVERITY IN CHRONIC PLAQUE PSORIASIS

    Nov 1, 2019, 00:00

  • PRO11 FACTORS ASSOCIATED WITH BLEEDING EXPERIENCE IN HEMOPHILIA A PATIENTS IN SOUTH KOREA

    Nov 1, 2019, 00:00

  • CV2 NATIONAL SAVINGS FROM TELEHEALTH CARE IN HEART FAILURE RESULTS FROM THE DANISH TELECARE NORTH TRIAL

    Nov 1, 2019, 00:00

  • PNS200 ANALYSIS OF HOSPITAL USE OF SURGERY WARDS TO OPTIMIZE HOSPITAL INFRASTRUCTURE PLANNING

    Nov 1, 2019, 00:00

  • PSU10 ECONOMIC EVALUATION OF HYSTERECTOMY IN THE REAL CLINICAL PRACTICE: ROBOT-ASSISTED VERSUS CONVENTIONAL LAPAROSCOPIC

    Nov 1, 2019, 00:00

  • AI4 GENERAL PAIRWISE COMPARISONS TO SUPPORT QUANTITATIVE MULTIPLE CRITERIA DECISION ANALYSIS

    Nov 1, 2019, 00:00

  • PRS61 A COMPARISON OF EUROPEAN MEDICINES AGENCY (EMA) AND FOOD AND DRUG ADMINISTRATION (FDA) PATIENT-REPORTED OUTCOME (PRO) GUIDANCES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PRS37 CHARACTERISTICS OF US ADULTS WITH SELF-REPORTED CHRONIC COUGH: 2018 CHRONIC COUGH SURVEY

    Nov 1, 2019, 00:00

  • PNS323 WHAT IS A VALID MAPPING ALGORISM IN COST-UTILITY ANALYSES? AN ANSWER FROM A MISSING DATA PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL

    Nov 1, 2019, 00:00

  • PCV24 REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL

    Nov 1, 2019, 00:00

  • PMD38 THE CLINICAL AND ECONOMIC ANALYSES OF VIDEO ASSISTED THORACOSCOPIC SURGERY FOR LOBECTOMY: EXPERIENCE FROM A TOP ACADEMIC MEDICAL CENTER IN CHINA

    Nov 1, 2019, 00:00

  • PBI13 TNF-ALPHA INHIBITORS IN THE CZECH REPUBLIC: HOW BIOSIMILARS AFFECT OVERALL CONSUMPTION AND COSTS?

    Nov 1, 2019, 00:00

  • PRS41 IDENTIFICATION OF POTENTIALLY UNDIAGNOSED PATIENTS WITH NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE USING MACHINE LEARNING APPLIED TO PRIMARY CARE DATA IN UK

    Nov 1, 2019, 00:00

  • PGI17 COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

    Nov 1, 2019, 00:00

  • Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

    Nov 1, 2019, 00:00

  • PMU71 EFFECTIVE IMPLEMENTATION OF BIOSIMILAR MEDICINE AT PATENT EXPIRATION TO ACHIEVE OPTIMAL FINANCIAL GAIN: BEST PRACTICE MODEL WITH ADALIMUMAB AS CASE

    Nov 1, 2019, 00:00

  • PGI51 PSYCHOMETRIC EVALUATION OF NASH-CHECK, A PATIENT-REPORTED OUTCOME MEASURE FOR NONALCOHOLIC STEATOHEPATITIS

    Nov 1, 2019, 00:00

  • PDB67 MAIN PREDICTORS OF DIABETES MELLITUS TYPE 2 (DM2T) IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PNS230 CALL FOR EFFECTIVE GUIDANCE: ASSESSMENT OF PHARMACOTHERAPEUTIC GUIDELINES IMPLEMENTATION

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PSS4 COST-EFFECTIVENESS ANALYSIS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION (CNV) IN CHINA

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PDG44 JOINT HTA AND DRUG PRICING COLLABORATIONS IN EU: BY WHOM AND WHEN TO BE PURSUED?

    Nov 1, 2019, 00:00

  • PNS410 DATA FROM EXPANDED ACCESS PROGRAMS: TREATMENT FIRST, COLLECTION SECOND. AN OVERVIEW OF FDA AND EMA REGULATORY APPROVALS.

    Nov 1, 2019, 00:00

  • PMH34 THE ECONOMIC BURDEN OF SCHIZOPHRENIA: A REAL-WORLD DATA ANALYSIS IN ITALY

    Nov 1, 2019, 00:00

  • PDG86 ECONOMIC EVALUATION FOR PRICING AND REIMBURSEMENT OF NEW DRUGS IN SPAIN: FABLE OR DESIDERATUM?

    Nov 1, 2019, 00:00

  • PCV123 DETERMINANTS OF POOR QUALITY OF LIFE AND HIGH HEALTH CARE RESOURCE CONSUMPTION IN HEART FAILURE PATIENTS IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • PMS56 CURRENT PATTERNS OF CARE IN THE ASSESSMENT AND TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

    Nov 1, 2019, 00:00

  • PCN410 USE OF EXTERNAL INFORMATION FROM HISTORICAL TRIAL DATA TO IMPROVE SURVIVAL ESTIMATIONS ON IMMATURE SURVIVAL DATA IN MULTIPLE MYELOMA (MM)

    Nov 1, 2019, 00:00

  • PNS85 SELF-MEDICATION PRACTICES AMONG PATIENTS IN SAUDI ARABIA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Injury Trauma - Organizational Practices

    Nov 1, 2019, 00:00

  • NO Specific Disease - Economic Evaluation

    Nov 1, 2019, 00:00

  • PSY40 ASSESSING THE QUALITY AND COHERENCE OF NETWORK META-ANALYSES OF BIOLOGICS IN PLAQUE PSORIASIS: WHAT DOES ALL THIS EVIDENCE SYNTHESIS TELL US?

    Nov 1, 2019, 00:00

  • PNS217 HOW CENTRAL LIMIT THEOREM RELATES TO THE SELECTION OF DISTRIBUTIONS FOR PROBABILISTIC SENSITIVITY ANALYSIS

    Nov 1, 2019, 00:00

  • PMH70 DIRECT HEALTHCARE COSTS FOR THE MANAGEMENT OF PATIENTS WITH OPIOID USE DISORDER TREATED WITH METHADONE AND BUPRENORPHINE/NALOXONE IN REAL-WORLD SETTING IN SPAIN. COSTEDOPIA STUDY

    Nov 1, 2019, 00:00

  • PNS286 SYSTEMATIC REVIEW ON THE ECONOMIC EVALUATION OF THE NON-INVASIVE PRENATAL TESTING

    Nov 1, 2019, 00:00

  • PCN36 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PIT8 ESTIMATION OF THE ECONOMIC BURDEN ASSOCIATED WITH 90-DAY COMPLICATIONS FOLLOWING INTERTROCHANTERIC HIP FRACTURE

    Nov 1, 2019, 00:00

  • PNS14 TOWARDS CONSISTENCY AND COHERENCE IN UNDERSTANDING THE ECONOMIC IMPACT OF DISEASE

    Nov 1, 2019, 00:00

  • PND93 WHAT GOOD ARE DIGITAL TECHNOLOGIES IN ALZHEIMER'S DISEASE RESEARCH? - A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN117 COST-UTILITY ANALYSIS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY VERSUS TRASTUZUMAB AND CHEMOTHERAPY FOR THE ADJUVANT TREATMENT OF PATIENTS WITH HER2+ EARLY BREAST CANCER IN SPAIN

    Nov 1, 2019, 00:00

  • PCN439 DEVELOPING A DISCRETE-EVENT SIMULATION TO STUDY THE INFLUENCE OF WAITING TIMES ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PSY53 PATIENT PREFERENCES IN THE TREATMENT OF HEMOPHILIA: A LATENT CLASS ANALYSIS

    Nov 1, 2019, 00:00

  • PIN92 DO INTERNATIONAL MIGRANTS FACE HIGHER BACTERIAL DRUG RESISTANCE COMPARED TO NATIVES? A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PRS10 UNDERSTANDING EMPHYSEMA BURDEN AND TREATMENT PATTERNS IN THE UNITED STATES: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PRO12 HOW DOES RISDIPLAM COMPARE IN INFANTILE ONSET SPINAL MUSCOLAR ATROPHY (SMA)? PRELIMINARY INDIRECT TREATMENT COMPARISONS BASED ON FIREFISH PART 1 DATA

    Nov 1, 2019, 00:00

  • PCV19 COMPARATIVE RISK OF HEART FAILURE HOSPITALIZATIONS ASSOCIATED WITH DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN TYPE 2 DIABETES PATIENTS: A POPULATION-BASED COHORT STUDY

    Nov 1, 2019, 00:00

  • PMU95 IS THERE REGIONAL VARIATION IN WORSE AND SLOWER COST/QALY HTA OUTCOMES FOR COMBINATION PRODUCTS INVOLVING TWO VS. ONE MANUFACTURER?

    Nov 1, 2019, 00:00

  • PIN4 A NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL VERSUS NEURAMINIDASE INHIBITORS IN THE TREATMENT OF INFLUENZA VIRUS INFECTION IN OTHERWISE HEALTHY AND HIGH-RISK ADULTS

    Nov 1, 2019, 00:00

  • PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIH58 THE EFFECT OF LONG-LASTING INTAKE OF MG AND B12ON THE MOTHER AND THE INTRA-UTERINE DEVELOPMENT OF THE FOETUS AS WELL AS THE OUTCOME OF DELIVERY

    Nov 1, 2019, 00:00

  • PDB37 A SYSTEMATIC REVIEW AND QUALITY APPRAISAL OF COST-EFFECTIVENESS ANALYSIS OF INSULIN PUMPS COMPARED WITH MULTIPLE DAILY INJECTIONS IN TYPE 1 DIABETES PATIENTS

    Nov 1, 2019, 00:00

  • PPM5 COSTS OF IN-HOUSE MUTATIONAL-TESTING AND IMPLICATIONS FOR ECONOMIC EVALUATION: A CASE EXAMPLE OF NON-SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2019, 00:00

  • PMH29 ESTIMATING A PREFERENCE-BASE INDEX FROM THE RECOVERING QUALITY OF LIFE MEASURE FOR ECONOMIC EVALUATION IN THE AREA OF MENTAL HEALTH: VALUATION OF REQOL-UI

    Nov 1, 2019, 00:00

  • PRS43 SOCIAL BURDEN AND MEDICAL COST OF COPD IN KOREA

    Nov 1, 2019, 00:00

  • PCV34 RIVAROXABAN PLUS ASPIRIN FOR THE PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE

    Nov 1, 2019, 00:00

  • PSY28 EPIDEMIOLOGY OF ATOPIC DERMATITIS IN SCHOOLCHILDREN AND ADOLESCENTS IN ITALY: A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2019, 00:00

  • PRO99 MULTI-CRITERIA DECISION ANALYSIS (MCDA) OF ELTROMBOPAG OLAMINE IN THE TREATMENT OF PATIENTS WITH REFRACTORY SEVERE APLASTIC ANEMIA UNDER THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL: A HEALTH TECHNOLOGY ASSESSMENT (HTA) ALTERNATIVE MODEL

    Nov 1, 2019, 00:00

  • PNS24 NORDIC COLLABORATIONS ON PROCUREMENT AND HEALTH TECHNOLOGY ASSESSMENT: CONCEPTS, COMPONENTS, AND OUTLOOK

    Nov 1, 2019, 00:00

  • PIN98 NATIONAL BURDEN OF SEPSIS IN INDONESIA: AN ANALYSIS BASED ON FOCAL INFECTIONS

    Nov 1, 2019, 00:00

  • PRO39 CONCEPTUAL FRAMEWORK FOR EVALUATING THE COST-EFFECTIVENESS OF A GENE THERAPY FOR HAEMOPHILIA B

    Nov 1, 2019, 00:00

  • PCN27 INTRAPATIENT COMPARISONS IN SINGLE ARM TRIALS FOR TUMOR AGNOSTIC INDICATIONS WITH APPLICATION TO ENTRECTINIB

    Nov 1, 2019, 00:00

  • PCV11 BURDEN OF HOSPITALISATIONS/READMISSIONS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION – A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCV126 PATIENT PREFERENCES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Individual's Health - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PBI62 REAL-WORLD EVIDENCE ON THERAPEUTIC DRUG MONITORING OF TNF-INHIBITORS IN INFLAMMATORY BOWEL DISEASE

    Nov 1, 2019, 00:00

  • PCN367 STOOL DNA TESTING FOR EARLY DETECTION OF COLORECTAL CANCER

    Nov 1, 2019, 00:00

  • PMU134 PATIENT CENTRICITY? PATIENT NOISE IN SOCIAL MEDIA AND SUPPORT PROGRAMS IN THE GERMAN HEALTHCARE ENVIRONMENT

    Nov 1, 2019, 00:00

  • PCV93 RESOURCE USE AND COSTS OF ACUTE CORONARY SYNDROME: A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PGI33 THE COST-EFFECTIVENESS OF FAECAL MICROBIOTA TRANSPLANTATION VS. ANTIBIOTICS FOR PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • HT4 INCLUSION OF PATIENT INPUT IN VALUE AND HEALTH TECHNOLOGY ASSESSMENT

    Nov 1, 2019, 00:00

  • PMH56 THE IMPACT OF PHYSICAL AND MENTAL STRESS ON THE PRODUCTIVITY LOSS IN JAPANESE WORKPLACE

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PGI55 QUALITY OF LIFE AND PATIENT PREFERENCE AMONG DANISH PATIENTS WITH ULCERATIVE COLLITIS - RESULTS FROM A SURVEY STUDY

    Nov 1, 2019, 00:00

  • PCN95 COST-EFFECTIVENESS ANALYSIS OF GERMLINE BRCA MUTATION TESTING AND OLAPARIB TREATMENT IN METASTATIC BREAST CANCER: AN EVALUATION OF CODEPENDENT TECHNOLOGIES

    Nov 1, 2019, 00:00

  • PCN93 HEALTH RESOURCE UTILIZATION IN ADVANCED OVARIAN AND ENDOMETRIAL CANCER IN A UNITED STATES INSURANCE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PMU143 PATIENT CENTRICITY IN PATIENT PREFERENCE STUDIES: INTERVIEWS WITH PATIENTS

    Nov 1, 2019, 00:00

  • PSY19 A COST PER RESPONDER ANALYSIS OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS FOR TREATMENT OF MODERATE TO SEVERE PSORIASIS PATIENTS OVER 1 YEAR IN MOROCCO

    Nov 1, 2019, 00:00

  • PMU78 APPLICATION OF MACHINE LEARNING TECHNIQUES IN EARLY DISEASE DETECTION: A REVIEW

    Nov 1, 2019, 00:00

  • PDB74 USING FRENCH ADMINISTRATIVE DATABASE TO ASSESS PATIENTS WITH ADVANCED NON-ALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • PMD20 COST EFFECTIVENESS ANALYSIS OF IMPLANTABLE CARDIAC MONITORS TO DETECT ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN79 A TARGETED LITERATURE REVIEW (TLR) OF THE EPIDEMIOLOGY AND ECONOMIC BURDEN OF ACUTE MYELOID LEUKEMIA (AML)

    Nov 1, 2019, 00:00

  • PSU35 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A COMMERCIAL CLAIMS DATABASE STUDY WITH TWO-YEAR FOLLOW-UP

    Nov 1, 2019, 00:00

  • PCN304 REIMBURSEMENT AND PAYER MANAGEMENT OF IMMUNE CHECKPOINT INHIBITORS IN KEY EUROPEAN MARKETS

    Nov 1, 2019, 00:00

  • PBI19 GENE THERAPIES: HOW WILL INDICATION-BASED PRICING AFFECT PATIENT ACCESS AND COST-CONTAINMENT MECHANISMS FOR PAYERS?

    Nov 1, 2019, 00:00

  • PBI29 LITERATURE REVIEW ON TOTAL MEDICAL COSTS AND COST COMPONENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPIES

    Nov 1, 2019, 00:00

  • PBI45 UPTAKE OF BIOSIMILAR INFLIXIMAB: BUDGET SAVINGS OR MARKET EXPANSION ACROSS COUNTRIES?

    Nov 1, 2019, 00:00

  • PSY44 ECONOMIC BURDEN OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) TO PATIENTS: COMPARATIVE STUDY

    Nov 1, 2019, 00:00

  • Personalized Regulatory

    Nov 1, 2019, 00:00

  • PRS62 ASSESSMENT OF PRESCRIPTION PATTERN AND EVALUATION OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2019, 00:00

  • PSU11 ROBOTIC VS LAPAROSCOPIC RIGHT HEMICOLECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PMU138 EXPLORATIVE SCOPING REVIEW AND BIBLIOMETRIC ANALYSIS OF BIG DATA APPLICATIONS FOR MEDICATION ADHERENCE

    Nov 1, 2019, 00:00

  • NO Specific Disease - Clinical Outcomes

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PDG50 PHARMACEUTICAL PRICING POLICIES IN QATAR AND LEBANON: NARRATIVE REVIEW AND DOCUMENT ANALYSIS

    Nov 1, 2019, 00:00

  • PDB90 IS IT POSSIBLE TO AUTOMATE A SYSTEMATIC LITERATURE REVIEW?

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PMD55 THE LEARNING CURVE AS A BARRIER IN THE CONDUCT OF RANDOMIZED CONTROLLED TRIALS WITH MEDICAL DEVICES - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS116 COMPARATIVE PRICING POLICY ANALYSIS BETWEEN DENMARK AND FRANCE.

    Nov 1, 2019, 00:00

  • PNS103 PHARMACY RESEARCH BASIC KNOWLEDGE IN THE KINDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PRS13 COST-UTILITY ANALYSIS OF MACITENTAN IN COMPARISON WITH BOSENTAN IN PULMONARY ATRIAL HYPERTENSION (PAH)

    Nov 1, 2019, 00:00

  • PMH67 ANALYSIS OF PSYCHOTROPIC MEDICATIONS PRESCRIPTIONS IN TURKEY

    Nov 1, 2019, 00:00

  • PRO76 ITALIAN 648/96 LAW APPLICATION BETWEEN JAN 2013 AND MAY 2019: FOCUS ON ORPHAN DRUGS

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PNS164 PHARMACOECONOMIC ASSESSMENT AND DRUG COSTS OF TREATMENTS FOR CANCER AND RARE DISEASES IN IRELAND

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PND115 PATIENT REALITIES IN MIGRAINE. LITERATURE REVIEW ENHANCED BY SOCIAL MEDIA

    Nov 1, 2019, 00:00

  • PSU33 REDUCTION IN DISCECTOMY TIME AND INSTRUMENT PASSES WITH THE CONCORDE® CLEAR MIS DISCECTOMY DEVICE FOR TRANSFORAMINAL LUMBAR INTERBODY FUSION DISCECTOMY

    Nov 1, 2019, 00:00

  • PDB95 RISK FACTOR CLUSTERING AND THE ECONOMIC MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)

    Nov 1, 2019, 00:00

  • MT4 COST ANALYSIS OF INTEGRATED VERSUS CONVENTIONAL OPERATING ROOMS

    Nov 1, 2019, 00:00

  • PND33 THE CLINICAL AND ECONOMIC BURDEN OF OBSTRUCTIVE SLEEP APNEA IN ADULTS: A COST-OF-ILLNESS ANALYSIS

    Nov 1, 2019, 00:00

  • PNS257 PERCEPTIONS ON THE PHARMACISTS' ROLE IN HTA DECISION MAKING IN GREECE

    Nov 1, 2019, 00:00

  • PRS19 BURDEN OF DISEASE OF FIBROSING INTERSTITIAL LUNG DISEASES IN EUROPE: THE BUILDUP PROJECT

    Nov 1, 2019, 00:00

  • PNS168 REFERENCE PRICE GROUPS (RPG) DEFINED FROM 2008 TO 2018 IN GERMANY - A DETAILED OVERVIEW AND DISCUSSION

    Nov 1, 2019, 00:00

  • Neurological Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PIN56 EXCESS HEALTHCARE RESOURCE UTILISATION ASSOCIATED WITH PERTUSSIS INFECTION IN OLDER ADULTS

    Nov 1, 2019, 00:00

  • PMH15 BUDGET IMPACT ANALYSIS OF SCHIZOPHRENIA TREATMENT IN INDONESIA

    Nov 1, 2019, 00:00

  • PRO67 UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PUK25 THE EFFECTIVENESS OF A DIGITAL PELVIC FLOOR TRAINING PROGRAM IN THE TREATMENT OF URINARY INCONTINENCE - A REAL WORLD EVALUATION

    Nov 1, 2019, 00:00

  • PCV147 DATA QUALITY EVALUATION OF 5 MUNICIPAL AND PROVINCIAL CLAIMS DATABASES OF FUJIAN PROVINCE IN CHINA

    Nov 1, 2019, 00:00

  • Infectious Diseases - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PND5 OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES: GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE

    Nov 1, 2019, 00:00

  • PUK33 PATIENT INSIGHTS FOR COMPLEMENT 3 GLOMERULOPATHY (C3G) USING SOCIAL MEDIA LISTENING

    Nov 1, 2019, 00:00

  • PIN25 EXPLORATORY ANALYSIS OF THE ECONOMICALLY JUSTIFIABLE PRICE OF AN RSV VACCINE FOR THE ELDERLY IN THE NETHERLANDS AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PGI22 HEALTH ECONOMIC EVALUATION OF EARLY LAPAROSCOPIC CHOLECYSTECTOMY FOR THE PATIENT WITH GALLSTONE DISEASE. A MICRO-COSTING ANALYSIS

    Nov 1, 2019, 00:00

  • PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PNS264 AN ASSESSMENT OF THE RECOMMENDATIONS MADE BY NICE'S MEDICAL TECHNOLOGIES EVALUATION PROGRAMME, AND WHETHER THE RECOMMENDATIONS SUPPORT MTEP'S STATED AIMS.

    Nov 1, 2019, 00:00

  • PDB89 COST-EFFECTIVENES ANALYSIS OF USING PEGVISOMANT FOR TREATMENT OF ACROMEGALY IN RUSSIA

    Nov 1, 2019, 00:00

  • PIH10 ANALYSING PRESCRIBING PATTERNS AND COSTS OF DRUG TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PDG56 BIOSIMILAR MARKET DYNAMICS IN KOREA

    Nov 1, 2019, 00:00

  • PDG55 RISK SHARING AGREEMENT ON PRESCRIPTION DRUGS: 5 YEARS EXPERIENCE OF THE KOREA NATIONAL HEALTH INSURANCE

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Medical Technologies

    Nov 1, 2019, 00:00

  • PMD51 EVALUATING THE USE AND OUTCOMES OF DIGITALLY ASSISTED VITREO-RETINAL SURGERY: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PBI5 IS ICER INCREASING INFLUENCE IN THE USA OVER TIME?

    Nov 1, 2019, 00:00

  • PMS11 A RETROSPECTIVE COHORT ANALYSIS OF THE BURDEN OF TOTAL KNEE ARTHROPLASTY IN JAPAN

    Nov 1, 2019, 00:00

  • PCN57 A MULTI-STAKEHOLDER PERSPECTIVE ON THE CHALLENGES IN DEMONSTRATING THE LONG-TERM BENEFIT OF CANCER IMMUNOTHERAPY

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCV106 ANTIHYPERTENSIVE AGENT UTILIZATION AMONG PATIENTS WITH UNCONTROLLED HYPERTENSION IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PNS92 PUBLIC AWARENESS OF NURSING REFORM IN THE REPUBLIC OF KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PRO101 ORPHAN DRUG REIMBURSEMENT IN ENGLAND AND IMPLICATIONS FOR PATIENT ACCESS

    Nov 1, 2019, 00:00

  • PCN380 A TARGETED REVIEW EVALUATING UNCERTAINTY IN SINGLE TECHNOLOGY APPRAISAL SUBMISSIONS FOR TREATMENTS APPROVED FOR USE SINCE THE INTRODUCTION OF THE 'NEW' CANCER DRUGS FUND

    Nov 1, 2019, 00:00

  • PCN2 REAL-WORLD DATA FOR NON-SMALL-CELL LUNG CANCER PATIENTS WITH POSITIVE EGFR MUTATION IN GREECE: PRELIMINARY RESULTS FROM A REGISTRY

    Nov 1, 2019, 00:00

  • PMS33 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PNS149 STATUS OF COMPASSIONATE USE PROGRAMMES (CUP) IN THE EU-5 (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM)

    Nov 1, 2019, 00:00

  • PMU48 PR PROCESS IN ITALY: A FOCUS ON NEGOTIATION OUTCOMES OF INNOVATIVE DRUGS

    Nov 1, 2019, 00:00

  • PSY43 HEALTH STATE UTILITIES ASSOCIATED WITH SICKLE CELL DISEASE AND ITS TREATMENT: LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Injury Public Health

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PNS276 DOES FDA BREAKTHROUGH DESIGNATION AFFECT HTA RECOMMENDATIONS IN TERMS OF TIMING AND OUTCOME?

    Nov 1, 2019, 00:00

  • PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) A ...

    Nov 1, 2019, 00:00

  • PBI84 BASELINE RHEUMATOID ARTHRITIS SEVERITY AMONG PATIENTS RECEIVING BIOLOGIC DMARDS: FINDINGS FROM A REAL-WORLD DATABASE

    Nov 1, 2019, 00:00

  • ON8 CHEMOTHERAPY INDUCED NAUSEA VOMITING: VALIDATION OF RISK SCORING ALGORITHM IN PATIENTS WITH GYNECOLOGICAL AND GASTROINTESTINAL CANCERS

    Nov 1, 2019, 00:00

  • PCV88 PHARMACY COLLECTION OF PRESCRIBED SECONDARY PREVENTIVE DRUG THERAPY AFTER MYOCARDIAL INFARCTION - A NORWEGIAN NATIONWIDE COHORT STUDY

    Nov 1, 2019, 00:00

  • PNS98 A QUALITATIVE EXPLORATION OF KNOWLEDGE, ATTITUDE AND PRACTICES OF PHYSICIANS ABOUT PHARMACOVIGIILANCE ACTIVITIES IN TERTIARY CARE HOSPITALS OF LAHORE, PAKISTAN

    Nov 1, 2019, 00:00

  • PND4 CHARACTERISTICS OF MIGRAINE PATIENTS IN PORTUGUESE HEADACHE SPECIALIST CENTERS

    Nov 1, 2019, 00:00

  • PMD52 MEDICAL DEVICES AND SUSTAINABILITY: CLAIMS AND EVIDENCE IN NICE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

    Nov 1, 2019, 00:00

  • PCN58 FOUR-STATE MARKOV MODEL FOR IMMUNO-ONCOLOGIC THERAPIES

    Nov 1, 2019, 00:00

  • PBI25 COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL

    Nov 1, 2019, 00:00

  • Medical Devices - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN59 CHARACTERISING ERRORS INCURRED BY MODEL SELECTION BASED ON AIC FOR EXTRAPOLATION OF SURVIVAL IN HEALTH TECHNOLOGY ASSESSMENT - A SIMULATION STUDY

    Nov 1, 2019, 00:00

  • PIN20 EXPECTED COST-EFFECTIVENESS OF HIGH DOSE VERSUS ADJUVANTED STANDARD DOSE TRIVALENT INFLUENZA VACCINES IN ENGLAND AND WALES: ASSESSMENTS USING DIRECT AND INDIRECT COMPARATIVE EFFECTIVENESS DATA

    Nov 1, 2019, 00:00

  • PCN252 RISK OF LUNG CANCER AMONG SMOKING WOMEN TREATED WITH RADIOTHERAPY FOR PRIMARY BREAST CANCER: FRENCH PROSPECTIVE COHORT STUDY

    Nov 1, 2019, 00:00

  • PNS366 UNDERSTANDING THE ROLE OF ANCHOR CORRELATIONS IN THE CALCULATION OF MEANINGFUL CHANGE THRESHOLDS FOR HEALTH-RELATED QUALITY OF LIFE RESEARCH

    Nov 1, 2019, 00:00

  • AI3 DEVELOPMENT OF A DECISION-AID FOR PATIENTS WITH DEPRESSION CONSIDERING TREATMENT OPTIONS: PREDICTION OF TREATMENT RESPONSE USING A DATA-DRIVEN APPROACH

    Nov 1, 2019, 00:00

  • PCN4 DINUTUXIMAB BETA WITH ISOTRETINOIN VERSUS ISOTRETINOIN ALONE IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: IMPACT ON LONG-TERM SURVIVAL

    Nov 1, 2019, 00:00

  • PMH59 VALIDATION OF A SCREENING INSTRUMENT OF ADDICTION TO FAST FOOD IN SPANISH GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PCN417 INFLUENCE 2.0: A TIME-DEPENDENT MODEL TO PREDICT LOCOREGIONAL RECURRENCE AND SECOND PRIMARIES IN EARLY BREAST CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PND21 PROJECT HERCULES: A NEW PARADIGM FOR PATIENT-CENTRED COLLABORATION IN HTA

    Nov 1, 2019, 00:00

  • PCV12 ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH HISTORY OF MYOCARDIAL INFARCTION IN FRANCE USING SNDS DATABASE

    Nov 1, 2019, 00:00

  • Infectious Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PIN13 FIRST EMA-EUNETHTA PARALLEL CONSULTATION FOR VACCINES

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PNS12 FACTORS TO BE CONSIDERED TO ENSURE ACCEPTABILITY OF HISTORICALLY CONTROLLED STUDIES BY HTA BODIES

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • Surgery - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN427 ASSESSING THE PERFORMANCE OF PARAMETRIC SURVIVAL MODELS USING REAL WORLD EVIDENCE IN CML, LUNG AND PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PDG100 PARENTERAL PREPARATIONS STEWARDSHIP IN A TEACHING HOSPITAL IN NIGERIA

    Nov 1, 2019, 00:00

  • PMU79 TWO YEARS OF A HOSPITAL-WIDE FULLY INTEGRATED BIOSIMILARS UTILIZATION MANAGEMENT SYSTEM: AN EFFICIENCY ANALYSIS

    Nov 1, 2019, 00:00

  • PDG89 ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) MARKET ACCESS - A CONTINUING CHALLENGE

    Nov 1, 2019, 00:00

  • PCN105 COST-UTILITY OF NIVOLUMAB FOR RECURRENT OR METASTATIC HEAD AND NECK CANCER (R/M SCCHN) IN FRANCE

    Nov 1, 2019, 00:00

  • PCN260 REVIEW OF BREAST CANCER MATHEMATIC AND EPIDEMIOLOGY MODELS

    Nov 1, 2019, 00:00

  • PBI51 TRENDS IN THE THERAPEUTIC BIOLOGICS ATHORIZED BY FDA, EMA AND THE SAUDI FDA IN THE PERIOD 1996-2018

    Nov 1, 2019, 00:00

  • PMU111 USE OF EXTERNAL COMPARATORS IN HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS

    Nov 1, 2019, 00:00

  • PND132 CLAIMS DATABASE ANALYSIS OF HEADACHE AND MIGRAINE IN SPAIN 2011-2016: PATIENT PROFILE, HEALTHCARE MANAGEMENT AND DIRECT MEDICAL COSTS

    Nov 1, 2019, 00:00

  • PMU17 COSTS ASSOCIATED WITH THE MANAGEMENT OF CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA IN ADULT PATIENTS UNDERGOING INVASIVE PROCEDURES IN SPAIN

    Nov 1, 2019, 00:00

  • PGI5 COLECTOMY FOR ULCERATIVE COLITIS IN THE UK: A REVIEW OF INCIDENCE AND COMPLICATIONS

    Nov 1, 2019, 00:00

  • PNS133 BEYOND INTERNATIONAL PRICING INDEX MODEL IN THE UNITED STATES - IMPACT TO GLOBAL PRICING STRATEGIES ACCESS TO INNOVATIVE MEDICINES

    Nov 1, 2019, 00:00

  • PNS211 SWOT ANALYSIS FOR CREATION OF HTA ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PNS118 DEVELOPMENT AND POTENTIALS OF HEALTH TECHNOLOGY ASSESSMENT SYSTEM IN KAZAKHSTAN.

    Nov 1, 2019, 00:00

  • PND111 DESIGN OF THE INDIVIDUALISED MEMORY DEPENDENT QUALITY OF LIFE (MEMORYDQOL) AND THE MEMORY TREATMENT SATISFACTION QUESTIONNAIRE (MEMORYTSQ) FOR PEOPLE WITH DEMENTIA USING EXISTING DQOL AND TSQ TEMPLATES AND ITEM LIBRARIES

    Nov 1, 2019, 00:00

  • PAM4 HEALTHCARE UTILIZATION AND HOSPITALIZATION COSTS AMONG FRAIL AND AT-NUTRITIONAL RISK OR MALNOURISHED OLDER ADULTS

    Nov 1, 2019, 00:00

  • PMD6 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A DUTCH HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • VALUE Assessment of Medical Technology

    Nov 1, 2019, 00:00

  • PMU74 FIRST 27 MONTHS OF CONDITIONAL REIMBURSEMENT IN FINLAND

    Nov 1, 2019, 00:00

  • PRO103 THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES

    Nov 1, 2019, 00:00

  • PRO139 A PATIENT-CENTRIC APPROACH TO COST OF ILLNESS RESEARCH: A CASE EXAMPLE OF PATIENT ENGAGEMENT TO IDENTIFY THE HIDDEN COSTS ASSOCIATED WITH BLINDNESS DUE TO INHERITED RETINAL DYSTROPHIES

    Nov 1, 2019, 00:00

  • PRO63 THE NATURAL HISTORY OF DUCHENNE MUSCULAR DYSTROPHY IN THE CORTICOSTEROID ERA: A SYSTEMATIC REVIEW OF STUDIES FROM CANADA AND THE US

    Nov 1, 2019, 00:00

  • PGI49 CHANGES IN HEALTH RELATED QUALITY OF LIFE IN CROHN'S DISEASE PATIENTS FOLLOWING MINDFULNESS-BASED COGNITIVE INTERVENTION: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL

    Nov 1, 2019, 00:00

  • PCN482 PATIENT-REPORTED OUTCOME MEASURES IN BREAST CANCER: A SYSTEMATIC REVIEW OF EORTC QLQ-C30, FACT-B, AND EORTC QLQ-BR23 DEVELOPMENT AND VALIDATION

    Nov 1, 2019, 00:00

  • PNS77 CHALLENGES OF STUDIES ON ECONOMIC EVALUATION IN CHILD HEALTH IN CHINA-BASED ON A REVIEW OF PUBLISHED LITERATURE

    Nov 1, 2019, 00:00

  • PRO141 ESTIMATING UTILITY WEIGHTS IN HEMOPHILIA A PATIENTS WITH INHIBITORS USING THE EQ-5D-5L TOOL: A COMPARISON OF EMICIZUMAB PROPHYLAXIS VERSUS ON-DEMAND TREATMENT WITH BYPASSING AGENTS

    Nov 1, 2019, 00:00

  • PCV43 BUDGET IMPACT ANALYSIS OF A DUAL-LAYER STENT RETRIEVER FOR THE TREATMENT OF LARGE VESSEL STROKES: A U.S. PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • RE2 THEMES IN THE DESIGN OF PHARMACEUTICAL VALUE-BASED CONTRACTS IN THE UNITED STATES AND EUROPE

    Nov 1, 2019, 00:00

  • Effect of Reflection and Deliberation on Health State Values: A Mixed-Methods Study

    Nov 1, 2019, 00:00

  • PRO64 MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA (MF-CTCL) EPIDEMIOLOGY AND TREATMENT PATHWAYS IN FRANCE AND SPAIN: NEW INSIGHTS FOR AN ACCURATE DESCRIPTION

    Nov 1, 2019, 00:00

  • PRO147 MAPPING PROQOLID TO RARE DISEASES: A ON-GOING COLLABORATION BETWEEN MAPI RESEARCH TRUST AND ORPHANET

    Nov 1, 2019, 00:00

  • PMD57 TOTAL HOSPITAL COSTS AND READMISSION RATE OF PATIENT-SPECIFIC CUTTING GUIDE IN TOTAL KNEE ARTHROPLASTY (TKA) PATIENTS

    Nov 1, 2019, 00:00

  • PMU10 CONSIDERATIONS FOR THE TRANSLATION AND LINGUISTIC VALIDATION OF CLINICAL OUTCOME ASSESSMENTS (COAS) IN VARIANTS OF SPANISH FOR THE UNITED STATES

    Nov 1, 2019, 00:00

  • PNS221 ANALYSIS OF HTA DOSSIERS SUBMISSION AND RECOMMENDATION REPORTS FOR DRUG PROCUREMENT AND REIMBURSMENT IN UKRAINE

    Nov 1, 2019, 00:00

  • PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

    Nov 1, 2019, 00:00

  • PSY4 THE USE OF EQ-5D VISUAL ANALOG SCALE (EQ-VAS) IN DISEASES AREAS WHERE EQ-5D IS INSENSITIVE TO CHANGES IN THE DISEASE STATUS: THE CASE OF LIPODYSTROPHY

    Nov 1, 2019, 00:00

  • PNS59 INCORPORATING THE PATIENT'S PERSPECTIVE IN ECONOMIC EVALUATIONS OF HEALTHCARE

    Nov 1, 2019, 00:00

  • PCN510 HEALTHCARE RESOURCE UTILISATION (HCRU) ASSOCIATED WITH TRANSCATHETER ARTERIAL CHEMOEMBOLISATION (TACE) TREATMENT IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS IN EUROPE

    Nov 1, 2019, 00:00

  • PGI19 COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE

    Nov 1, 2019, 00:00

  • PCV76 COMTEMPORARY HEART FAILURE TREATMENT PATTERN AND COST IN CHINESE PATIENTS POPULATIONS

    Nov 1, 2019, 00:00

  • PND59 BUDGET IMPACT ANALYSIS OF THE NATIONAL CLINICAL GUIDELINE FOR APPROPRIATE PRESCRIBING OF PSYCHOTROPIC MEDICATION IN PEOPLE WITH DEMENTIA

    Nov 1, 2019, 00:00

  • PMD56 NETWORK META-ANALYSIS OF THE USE OF ISTENT® INJECT MICROINVASIVE SURGERY IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS

    Nov 1, 2019, 00:00

  • PND14 CLINICALLY RELEVANT REDUCTION OF MIGRAINE SYMPTOMS BY FREMANEZUMAB IN PATIENTS WHO FAILED TO VALPROIC ACID TREATMENT

    Nov 1, 2019, 00:00

  • PRO104 DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • PIN101 ECONOMIC IMPACT OF ICU-ACQUIRED MULTI-DRUG RESISTANT BACTERIAL INFECTIONS: EVIDENCE FROM SOUTHERN EUROPE

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS41 A PRAGMATIC METHOD FOR COSTING IMPLEMENTATION STRATEGIES USING THE TIME-DRIVEN ACITVITY-BASED COSTING

    Nov 1, 2019, 00:00

  • PCN511 ASSOCIATED FACTORS AFFECTING RECURRENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA

    Nov 1, 2019, 00:00

  • PNS78 RECONCILING ACEA AND MCDA: IS THERE A WAY FORWARD FOR MEASURING COST-EFFECTIVENESS IN THE U.S. HEALTHCARE SETTING?

    Nov 1, 2019, 00:00

  • PSS16 ANTI-VEGF INTRAVITREAL INJECTIONS IN PORTUGAL: THE FIRST DECADE 2007-2017

    Nov 1, 2019, 00:00

  • PCN129 COST STRUCTURE ANALYSIS: DRUG THERAPY OF PATIENTS WITH STOMACH CANCER IN MOSCOW. ANALYSIS OF PATIENT DETECTION

    Nov 1, 2019, 00:00

  • PCN198 FRACTIONAL POLYNOMIAL MODELS FOR NETWORK META-ANALYSIS OF SURVIVAL DATA IN ECONOMIC EVALUATIONS: A CASE-STUDY ON THE COST-EFFECTIVENESS OF FULVESTRANT IN PREVIOUSLY-TREATED POSTMENOPAUSAL, OESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST ...

    Nov 1, 2019, 00:00

  • PND10 ANTI-TNF-α INHIBITORS IN PREVENTING ALZHEIMER'S DISEASE (AD): A RETROSPECTIVE REVIEW USING BOTH EMR AND CLAIMS DATA

    Nov 1, 2019, 00:00

  • PBI90 THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES

    Nov 1, 2019, 00:00

  • PMS6 QUALITY OF LIFE OF PATIENTS UNDERWENT IMPLANTATION OF KNEE ENDOPROSTHESIS

    Nov 1, 2019, 00:00

  • Patient Reported Outcomes Quality of Life Studies

    Nov 1, 2019, 00:00

  • CV3 MECHANICALLY EXPANDED VERSUS SELF-EXPANDING TRANSCATHETER AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH AORTIC STENOSIS: A BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PMU102 DIFFERENCES IN HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS BETWEEN EUROPEAN JURISDICTIONS: THE ROLE OF PRACTICE VARIATIONS

    Nov 1, 2019, 00:00

  • PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRS28 ECONOMIC AND ENVIRONMENTAL IMPACTS OF A VOLUNTARY SHIFT IN INHALER PRESCRIBING IN THE ENGLISH NHS

    Nov 1, 2019, 00:00

  • PNS387 MULTI-CRITERIA DECISIONAL ANALYSIS ON NON-EMERGENCY MEDICAL TRANSPORT IN HONG KONG CONTEXT

    Nov 1, 2019, 00:00

  • PSY3 DISEASE BURDEN OF RHEUMATOID ARTHRITIS IN CHINA

    Nov 1, 2019, 00:00

  • PCN199 COST-UTILITY ANALYSIS OF THE BI-, QUADRI-, AND NONA-VALENT HPV-VACCINE: A DECISION ANALYTIC MODEL

    Nov 1, 2019, 00:00

  • PCN216 THE SOCIETAL IMPACT OF LENALIDOMIDE IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA IN GERMANY

    Nov 1, 2019, 00:00

  • PCN171 COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS)

    Nov 1, 2019, 00:00

  • PIN48 THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN OF DRUG-RESISTANT TUBERCULOSIS IN INDIA

    Nov 1, 2019, 00:00

  • PNS338 DEVELOPMENT, VALIDATION AND ASSESSMENT OF RELIABILITY OF DDQ-KAP 16 QUESTIONNAIRE

    Nov 1, 2019, 00:00

  • PCN231 COST-EFFECTIVENESS OF REGORAFENIB FOR METASTATIC COLORECTAL CANCER IN THE CONTEXT OF THE HEALTHCARE SYSTEM OF KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PMU147 PUBLICATION PATTERNS OF HEALTH ECONOMIC OUTCOME DATA OVER 2 DECADES: AN INCREASE IN PEER-REVIEWED HEOR PUBLICATIONS ACROSS INFLAMMATORY DISEASES

    Nov 1, 2019, 00:00

  • PCV56 COST-EFFECTIVENESS OF THE SUSTAINED-RELEASE PACLITAXEL-ELUTING ELUVIA STENT COMPARED TO THE PACLITAXEL-COATED ZILVER PTX STENT FOR ENDOVASCULAR TREATMENT OF PERIPHERAL ARTERY DISEASE: A GERMAN STATUTORY SICKNESS FUND PERSPECTIVE.

    Nov 1, 2019, 00:00

  • PMS73 DEPRESCRIBING OF ANALGESICS AND REPLACEMENT WITH PHYSIOTHERAPY IN THE DEPARTMENT OF ORTHOPEDICS FOR KNEE OSTEOARTHRITIS PATIENTS

    Nov 1, 2019, 00:00

  • PNS184 THE VALUE OF BLOOD IN SUB-SAHARAN AFRICA

    Nov 1, 2019, 00:00

  • PNS354 MARKET ACCESS AS DEFINED BY MARKET ACCESS (MA), HEALTH ECONOMICS, AND OUTCOMES RESEARCH (HEOR) PROFESSIONALS

    Nov 1, 2019, 00:00

  • PCN506 MUTATION TESTING AND TREATMENT OF THE MOST COMMON ONCOLOGY DISEASES IN GERMANY: ANALYSIS OF AN ONCOLOGY EMR DATABASE

    Nov 1, 2019, 00:00

  • NO Specific Disease - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN478 HEALTH-RELATED QUALITY OF LIFE OF CANCER PATIENTS IN JAPAN: A POPULATION-BASED NATIONAL HEALTH AND WELLNESS SURVEY STUDY

    Nov 1, 2019, 00:00

  • PCN167 SELF-REPORTED OUT-OF-POCKET EXPENSES, INCOME LOSS, AND INFORMAL CARE INCURRED BY CANCER PATIENTS IN SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PNS374 CLINICAL BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN CAREGIVERS OF CANCER PATIENTS: RESULTS FROM LINKING ELECTRONIC HEALTH RECORDS TO PATIENT-REPORTED OUTCOMES

    Nov 1, 2019, 00:00

  • PIN65 COST-EFFECTIVENESS ANALYSIS ON ELDERLY PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS: CHALLENGING THE DUTCH HEALTH COUNCIL'S ADVICE

    Nov 1, 2019, 00:00

  • PND98 PATTERNS AND PREDICTION FOR COGNITIVE DECLINE IN ALZHEIMER'S PATIENTS AS ASSESSED BY THE MINI-MENTAL STATUS EXAM IN AN AMBULATORY ELECTRONIC MEDICAL RECORD

    Nov 1, 2019, 00:00

  • PCN440 NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS: HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE)

    Nov 1, 2019, 00:00

  • PCN331 HUMANISTIC BURDEN OF NEWLY DIAGNOSED VERSUS RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

    Nov 1, 2019, 00:00

  • PMU11 MAIN WEAKNESSES AND PROBLEMATICS OF CYBERSECURITY IN MEDICAL DEVICES

    Nov 1, 2019, 00:00

  • PRS40 CURRENT TREATMENT STATUS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IN JAPAN: A CLAIMS-BASED RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PDB127 BUDGET-IMPACT ANALYSIS (BIA) OF OBESITY FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PDB40 PREDICTIVE ANALYSIS OF COST AND CAPACITY EFFECTS OF THE DIGITALIZED SECONDARY CARE SERVICES FOR INSULIN-DEPENDENT DIABETES PATIENTS @ VIRTUAL HOSPITAL 2.0

    Nov 1, 2019, 00:00

  • PCN308 IDENTIFICATION OF VARIABLES THAT MAY INFLUENCE THE RECOMMENDATION INCLUDED IN THE THERAPEUTIC POSITIONING REPORT OF NEW ONCOLOGY PRODUCTS IN SPAIN

    Nov 1, 2019, 00:00

  • PCV10 EFFECT OF LOW PRIME VOLUME ON HEMATOCRIT IN CORONARY ARTERY BYPASS SURGERY

    Nov 1, 2019, 00:00

  • PRS5 TREATMENT PERSISTENCE AND EXACERBATIONS IN PATIENTS WITH ASTHMA INITIATING TREATMENT WITH INHALED CORTICOSTEROIDS AND LONG-ACTING BETA-ADRENERGIC AGONISTS (ICS/LABA): REAL-LIFE STUDY

    Nov 1, 2019, 00:00

  • PCN89 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN BELGIUM

    Nov 1, 2019, 00:00

  • PMU86 A REVIEW OF TOP COUNTRIES CONTRIBUTING TO POSTERS PRESENTED AT ISPOR EUROPE 2018

    Nov 1, 2019, 00:00

  • PNS169 PERSONAL MEDICAL HEALTH RECORDS REGULATION IN THE UNITED STATED, EUROPEAN UNION AND ISRAEL

    Nov 1, 2019, 00:00

  • PCV90 RISK FACTORS, USE OF HEALTH CARE RESOURCES, AND MORTALITY IN PATIENTS WITH MINOR ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK

    Nov 1, 2019, 00:00

  • PCN273 EPIDEMIOLOGY AND UNMET NEEDS OF BLADDER CANCER IN ITALY

    Nov 1, 2019, 00:00

  • AD3 ORAL ANTICOAGULANT PRESCRIPTION TRENDS, PROFILE USE AND DETERMINANTS OF ADHERENCE IN PATIENTS WITH ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PCV7 ESTIMATION THE PHYSICAL ACTIVITY OF HEART FAILURE PATIENTS BASED ON TELEMETRY DATA

    Nov 1, 2019, 00:00

  • PDB45 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): RESOURCE USE AND DIRECT COSTS

    Nov 1, 2019, 00:00

  • PNS23 THE IMPACT OF EARLY CENSORING ON THE PFS BY A MULTI-STATE MODEL

    Nov 1, 2019, 00:00

  • PDB63 COST-EFFECTIVENESS OF INSULIN PUMP AND CONTINUES GLUCOSE MONITORING VERSUS MULTIPLE DAILY INJECTIONS AND SELF-MONITORING OF BLOOD GLUCOSE IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS

    Nov 1, 2019, 00:00

  • Infectious Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • Real World DATA Information Systems

    Nov 1, 2019, 00:00

  • PMD39 HOSPITAL REIMBURSEMENT PATHWAYS FOR NEW EXAMINATION AND TREATMENT METHODS IN GERMANY

    Nov 1, 2019, 00:00

  • PCV97 BARRIERS THAT AFFECT ADHERENCE AND PERSISTENCE TO NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILATION (AF) IN TURKEY: A DELPHI STUDY.

    Nov 1, 2019, 00:00

  • PRO152 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE WESTERN ONTARIO MCMASTER UNIVERSITIES OSTEOARTHRITIS INVENTORY (WOMAC) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)

    Nov 1, 2019, 00:00

  • PDG27 ARE ACUTE THERAPIES AND CURATIVE DRUGS MORE AFFORDABLE THAN CHRONIC TREATMENTS IN RARE DISEASES? AN ANALYSIS OF THE TOP 20 MOST EXPENSIVE DRUGS IN THE US

    Nov 1, 2019, 00:00

  • PIH17 COST-EFFECTIVENESS OF INTERVENTIONS PREVENTING FALLS IN OLDER ADULTS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PRS46 TREATMENT OF SEVERE ASTHMA IN PORTUGAL: INSIGHTS FROM A PHYSICIANS' SURVEY

    Nov 1, 2019, 00:00

  • PCV124 REPORTING AND QUALITY OF PATIENT PREFERENCE STUDIES: A SYSTEMATIC LITERATURE REVIEW IN THE CARDIOVASCULAR DOMAIN

    Nov 1, 2019, 00:00

  • PUK15 INPATIENT COST-SAVINGS FROM THE USE OF SUCROFERRIC OXYHYDROXIDE IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING DIALYSIS IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PRO24 COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS VS. ON-DEMAND TREATMENT FOR HAEMOPHILIA B CHILDREN WITHOUT INHIBITOR IN CHINA

    Nov 1, 2019, 00:00

  • PNS159 PHARMACOECONOMICS AND HEALTH OUTCOME STUDIES IN TURKEY: ISPOR DATABASE SEARCH

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42 (current)
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • »